NASC (Nascent Pharma Holdings) Tariff Resilience Score: 0/10 (As of Jun. 28, 2026)


NASC Nascent Pharma Holdings Inc NASC
12 GF Score
Price $0.01
View Full Analysis

What is Nascent Pharma Holdings Tariff Resilience Score?

Nascent Pharma Holdings has the Tariff Resilience Score of 0, which implies that the company might have .

Nascent Pharma Holdings has Can B Corp relies on international suppliers for raw materials, making it vulnerable to tariffs. Its manufacturing is U.S.-based, but sales are global, increasing exposure. Limited historical data on tariff impacts and few alternative suppliers reduce resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Nascent Pharma Holdings might have .

Nascent Pharma Holdings  (OTCPK:NASC) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Nascent Pharma Holdings Tariff Resilience Score Related Terms

NASC
12GF Score
Nascent Pharma Holdings Inc NASC
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nascent Pharma Holdings Business Description

Address 44 East End Avenue, Hicksville, NY, USA, 11801
Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.
12GF Score

Get the complete analysis for NASC

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price